Comparison

Chlorpromazine (hydrochloride) European Partner

Item no. HY-B0407A-100mg
Manufacturer MedChem Express
CASRN 69-09-0
Amount 100 mg
Quantity options 100 mg 1 g 500 mg 5 g
Category
Type Inhibitors
Specific against other
Purity 99.90
Citations [1]Kamgar-Dayhoff P, et al. Multifaceted effect of chlorpromazine in cancer: implications for cancer treatment. Oncotarget. 2021 Jul 6;12(14):1406-1426. |[2]Shin SY, et al. The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt/mTOR pathway in human U-87MG glioma cells. Carcinogenesis. 2013 Sep;34(9):2080-9. |[3]Yang Z, et al. Cancer cell-intrinsic XBP1 drives immunosuppressive reprogramming of intratumoral myeloid cells by promoting cholesterol production. Cell Metab. 2022 Nov 2:S1550-4131(22)00461-2. |[4]Lee SJ, et al. Mechanism of inhibition by chlorpromazine of the human pain threshold sodium channel, Nav1.7. Neurosci Lett. 2017 Feb 3;639:1-7. |[5]Thomas D, et al. The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br J Pharmacol. 2003 Jun;139(3):567-74. |[6]Suzuki H, et al. Comparison of the anti-dopamine D₂ and anti-serotonin 5-HT(2A) activities of chlorpromazine, bromperidol, haloperidol and second-generation antipsychotics parent compounds and metabolites thereof. J Psychopharmacol. 2013 Apr;27(4):396-400.
ACS Nano. 2020 Nov 24;14(11):14698-14714.|Adv Funct Mater. 2020, 2004940.|Anal Chem. 2020 Sep 1;92(17):11921-11926.|Antivir Res. 2020 Jun;178:104786.|Arab J Chem. 2020, 13 (1): 2558-2567.|Biomaterials. 13 January 2022, 121373.|Br J Pharmacol. 2020 Aug;177(15):3473-3488. |Cell Commun Signal. 2019 May 23;17(1):49|Cell Commun Signal. 2020 Nov 4;18(1):176.|Comput Struct Biotec. 2021;19:1933-1943.|Emerg Microbes Infect. 2022 Dec;11(1):483-497.|Environ Sci Technol. 2021 Feb 11.|Front Cell Dev Biol. 18 March 2021.|Front Cell Dev Biol. 2021 Jul 7;9:687322.|Front Cell Dev Biol. 2023 Sep 8;11:1266198.|Front Immunol. 2021 Aug 2;12:686846.|Insect Sci. 2020 Aug;27(4):675-686.|Int J Biol Macromol. 14 March 2022.|J Am Chem Soc. 2018 Dec 12;140(49):17234-17240.|Langmuir. 2020 Sep 29;36(38):11374-11382.|mBio. 2025 Feb 18:e0378724.|Nat Commun. 2025 Mar 10;16(1):2368.|Pharmaceutics. 2024 Nov 21.|Phytother Res. 2023 Mar 8.|PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. |Sci China Life Sci. 2021 May 27;1-21.|Sci Total Environ. 2021, 146523.|Theranostics. 2019 May 31;9(13):3732-3753.|Theranostics. 2020 May 17;10(15):6581-6598. |Theranostics. 2021 May 24;11(15):7308-7321.|Toxins. 2021 Mar 2;13(3):184.|Virus Res. 2020 Jan 15;276:197806.|Viruses. 2021 May 31;13(6):1035.|ACS Nano. 2023 Apr 14.|Acta Biomater. 2024 Dec 25:S1742-7061(24)00776-1.|Acta Pharm Sin B. 2024 Aug 17.|Adv Funct Mater. 2023 Jan 15.|Adv Funct Mater. 2024 Oct 31.|Adv Mater. 2025 Jan 10:e2415030.|Adv Sci (Weinh). 2023 Apr 24;e2207017.|BBA-Gen Subjects. 2022: 130300.|Biol Res. 2023 Mar 11;56(1):10.|Br J Pharmacol. 2023 Feb 2.|Cell Commun Signal. 2023 May 4;21(1):99.|Cell Metab. 2022 Dec 6;34(12):2018-2035.e8.|Cell Metab. 2024 Jun 18:S1550-4131(24)00189-X.|Chem Eng J. 2024 Apr 15, 486 150125.|Chem Eng J. 2024 Sep 1.|Chem Mater. 2025 Jan 18.|Commun Biol. 2022 Nov 14;5(1):1248.|Drug Deliv Transl Res. 2023 Oct 3.|Extracell Vesicle. 2025 Jun.|J Control Release. 2024 Apr 24:370:140-151.|J Control Release. 2024 Oct 26:S0168-3659(24)00725-9.|J Control Release. 2025 Jan 8:379:45-58.|J Extracell Vesicles. 2024 Dec;13(12):e70025.|J Immunother Cancer. 2023 Jan;11(1):e005592.|J Leukoc Biol. 2024 Jul 16:qiae159.|J Med Chem. 2023 Dec 9.|J Pharm Anal. 2025 Jan 3.|J Virol. 2021 Sep 29;JVI0134521.|Microbiol Res. 2023 May 30;273:127421.|Nat Biomed Eng. 2024 Sep 13.|Nat Nanotechnol. 2024 Aug 26.|Pharm Biol. 2022 Dec;60(1):1679-1689.|Research Square Preprint. 2024 Apr 22.|Research Square Print. 2023 Mar 20.|Sci China Life Sci. 2024 Sep 13.|Virus Res. 2024 Oct 19:350:199485.
Smiles CN(C)CCCN1C2=C(C=CC=C2)SC3=CC=C(Cl)C=C13.Cl
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Shipping Condition Room temperature
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
Cancer-programmed cell death
Manufacturer - Targets
5-HT Receptor; Autophagy; Cytochrome P450; Dopamine Receptor
Shipping Temperature
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Molecular Weight
355.33
Product Description
Chlorpromazine hydrochloride is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine hydrochloride exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine hydrochloride also blocks hNav1.7 channels (IC50=25.9 μM; concentration-dependent) and HERG potassium channels (IC50=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine hydrochloride also can inhibit clathrin-mediated endocytosis[1][2][3][4][5].
Manufacturer - Research Area
Cancer; Neurological Disease; Cardiovascular Disease
Solubility
DMSO: ≥ 60 mg/mL|H2O: 100 mg/mL (ultrasonic)
Manufacturer - Pathway
Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling
Isoform
5-HT2 Receptor
Clinical information
Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close